Franklin Resources
AVBP icon

Franklin Resources’s ArriVent BioPharma AVBP Stock Holding History

Franklin Resources’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-256,422
Closed -$4.73M – 3295
2025
Q3 		$4.73M Buy
+256,422
New +$5.04M ﹤0.01% 1437

Other funds holding AVBP

IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Franklin Resources's AVBP Position: Q4 2025 in Review

Franklin Resources sold out of ArriVent BioPharma (AVBP) in Q4 2025, closing a stake of 256,422 shares — an estimated $4.73M sold.

Franklin Resources first reported a position in AVBP in Q3 2025 and held it in 1 quarter. The position peaked at $4.73M in Q3 2025. 121 funds tracked by Wall St. Rank hold AVBP as of Q4 2025.

  • Franklin Resources reported no remaining ArriVent BioPharma position as of Q4 2025 after selling out during the quarter.
  • Franklin Resources sold 256,422 ArriVent BioPharma shares in Q4 2025, an estimated $4.73M.
  • Franklin Resources first reported a position in ArriVent BioPharma in Q3 2025 and held it in 1 quarter.
  • Franklin Resources's ArriVent BioPharma position peaked at $4.73M in Q3 2025.
  • 121 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2025.

Based on Franklin Resources's 13F filing for Q4 2025, filed 11 Feb 2026.